Citadel Advisors
WHWK

Citadel Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Citadel Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$317K Sell
91,852
-7,098
-7% -$22.2K ﹤0.01% 10357
2025
Q4 		$239K Sell
98,950
-41,270
-29% -$94.7K ﹤0.01% 10654
2025
Q3 		$266K Buy
140,220
+111,682
+391% +$205K ﹤0.01% 10627
2025
Q2 		$53.4K Sell
28,538
-68,774
-71% -$120K ﹤0.01% 11734
2025
Q1 		$173K Buy
97,312
+35,277
+57% +$92.1K ﹤0.01% 10651
2024
Q4 		$196K Buy
62,035
+54,591
+733% +$124K ﹤0.01% 10495
2024
Q3 		$15.3K Sell
7,444
-485,692
-98% -$785K ﹤0.01% 12970
2024
Q2 		$720K Sell
493,136
-24,440
-5% -$45.3K ﹤0.01% 7305
2024
Q1 		$1.21M Buy
517,576
+109,854
+27% +$212K ﹤0.01% 6546
2023
Q4 		$824K Buy
407,722
+171,456
+73% +$719K ﹤0.01% 7073
2023
Q3 		$1.14M Sell
236,266
-22,627
-9% -$132K ﹤0.01% 6294
2023
Q2 		$1.77M Sell
258,893
-35,900
-12% -$279K ﹤0.01% 5364
2023
Q1 		$2.13M Sell
294,793
-2,201
-0.7% -$23.5K ﹤0.01% 5229
2022
Q4 		$3.81M Buy
296,994
+36,974
+14% +$483K ﹤0.01% 4327
2022
Q3 		$3.67M Buy
260,020
+26,765
+11% +$352K ﹤0.01% 4407
2022
Q2 		$2.87M Sell
233,255
-1,256
-0.5% -$18.7K ﹤0.01% 4838
2022
Q1 		$3.98M Buy
234,511
+3,982
+2% +$76.3K ﹤0.01% 4622
2021
Q4 		$5.57M Buy
230,529
+131,336
+132% +$3.3M ﹤0.01% 4114
2021
Q3 		$2.91M Buy
99,193
+2,249
+2% +$68.5K ﹤0.01% 5436
2021
Q2 		$2.46M Buy
96,944
+88,759
+1,084% +$2.03M ﹤0.01% 6093
2021
Q1 		$158K Buy
8,185
+2,711
+50% +$62.4K ﹤0.01% 11981
2020
Q4 		$80K Sell
5,474
-131,262
-96% -$2.81M ﹤0.01% 10346
2020
Q3 		$3.08M Buy
+136,736
New +$2.88M ﹤0.01% 3943
2020
Q2 		– Sell
-1,069
Closed -$9K – 10643
2020
Q1 		$9K Buy
+1,069
New +$9.86K ﹤0.01% 9439
2019
Q4 		– Sell
-1,422
Closed -$14K – 9889
2019
Q3 		$14K Buy
+1,422
New +$15.8K ﹤0.01% 9007

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors's WHWK Position: Q1 2026 in Review

Citadel Advisors reduced its Whitehawk Therapeutics (WHWK) stake by 7.2% in Q1 2026, selling an estimated $22.2K and leaving 91,852 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #10357.

Citadel Advisors first reported a position in WHWK in Q3 2019 and has held it in 25 quarters since. The position peaked at $5.57M in Q4 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Citadel Advisors held 91,852 shares of Whitehawk Therapeutics worth $317K as of Q1 2026.
  • Citadel Advisors sold 7,098 Whitehawk Therapeutics shares in Q1 2026, an estimated $22.2K.
  • Whitehawk Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10357 holding.
  • Citadel Advisors first reported a position in Whitehawk Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Whitehawk Therapeutics position peaked at $5.57M in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.